D. Back

David Back, D. Back, L. Else, 2013, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

LSD: The distribution of [3H]LSD in the reproductive system of the male rat and placental transfer in the female rat

D. Back, J. Singh, 1977, Experientia.

Interaction between amiodarone and sofosbuvir-based treatment for hepatitis C virus infection: potential mechanisms and lessons to be learned.

D. Back, D. Burger, David J Back, 2015, Gastroenterology.

The relative bioavailability of levonorgestrel and ethinylestradiol when administered in tablet and capsule form.

D. Back, M. Elstein, M. Cohen, 1987, Contraception.

Drug interactions involving oral contraceptive steroid therapy.

D. Back, Breckenridge Am, Orme Ml, 1984 .

Effect of ampicillin on mefloquine pharmacokinetics in thai males

D. Back, J. Karbwang, D. Bunnag, 1991, European Journal of Clinical Pharmacology.

The effect of oral contraceptive steroids and enzyme inducing drugs on sex hormone binding globulin capacity in women [proceedings].

A. Breckenridge, E. Perucca, D. Back, 1980, British journal of clinical pharmacology.

Mefloquine metabolism by human liver microsomes. Effect of other antimalarial drugs.

D. Back, J. Karbwang, K. N. Bangchang, 1992, Biochemical pharmacology.

The pharmacokinetics of mefloquine in man: lack of effect of mefloquine on antipyrine metabolism.

A. Breckenridge, D. Back, R. Howells, 1985, British journal of clinical pharmacology.

Treating Advanced HIV Infection

S. Khoo, M. Boffito, D. Back, 2003, Journal of acquired immune deficiency syndromes.

Etravirine plasma levels in a patient with decompensated liver disease

D. Back, M. Aboud, R. Kulasegaram, 2009, AIDS (London).

Potential problems with aqueous steroid solutions

S. Sim, D. Back, J. Tjia, 1983, The Journal of pharmacy and pharmacology.

Adsorption of pregnanediol-3α-glucuronide by plastics and glass

D. Back, M. Shaw, 1983 .

The lack of interaction between temafloxacin and combined oral contraceptive steroids.

D. Back, M. Orme, T. Mant, 1991, Contraception.

Therapy with oral contraceptive steroids and antibiotics.

D. Back, M. Orme, 1979, Journal of Antimicrobial Chemotherapy.

Alterations in Cerebrospinal Fluid Chemokines Are Associated With Maraviroc Exposure and In Vivo Metabolites Measurable by Magnetic Resonance Spectroscopy

J. Allsop, A. Winston, S. Taylor-Robinson, 2012, HIV clinical trials.

Lopinavir Measurement in Pleural Effusion in a Human Immunodeficiency Virus Type 1-Infected Patient with Kaposi's Sarcoma

G. di Perri, M. Boffito, D. Back, 2002, Antimicrobial Agents and Chemotherapy.

COVID‐19 treatment in patients with comorbidities: Awareness of drug‐drug interactions

C. Marzolini, S. Khoo, D. Back, 2020, British journal of clinical pharmacology.

The effect of bile pigments on the excretion of 14C-trimophonium glucuronide.

D. Back, T. N. Calvey, 1971, European journal of pharmacology.

The effect of genetic polymorphisms in CYP2C9 on sulphamethoxazole N-hydroxylation.

M. Pirmohamed, N. Kitteringham, B. K. Park, 1999, Pharmacogenetics.

Therapeutic Drug Monitoring

S. Khoo, D. Back, S. Gibbons, 2002, Journal of the International Association of Physicians in AIDS Care.

Darunavir concentrations exceed the protein-corrected EC50 for wild-type HIV in the semen of HIV-1-infected men

D. Back, Stephen Taylor, E. Smit, 2010, AIDS (London).

Penetration of efavirenz into the male genital tract: drug concentrations and antiviral activity in semen and blood of HIV-1-infected men.

D. Pillay, C. Sabin, D. Back, 2001, AIDS (London).

Intracellular and Plasma Pharmacokinetics of Nelfinavir and M8 in HIV-Infected Patients: Relationship with P-Glycoprotein Expression

D. Cornforth, M. Johnson, S. Khoo, 2004, Antiviral therapy.

Effect of oral contraceptive steroids on the clinical course of malaria infection and on the pharmacokinetics of mefloquine in Thai women.

A. Breckenridge, D. Back, S. Looareesuwan, 1988, Bulletin of the World Health Organization.

Efavirenz in an Obese HIV-Infected Patient – a Report and An In Vitro–In Vivo Extrapolation Model Indicate Risk of Underdosing

M. Battegay, C. Marzolini, D. Back, 2012, Antiviral Therapy.

Drug–drug interactions with direct‐acting antivirals: when do we need to care?

D. Back, F. Marra, 2020 .

Integrated efficacy and safety of glecaprevir/pibrentasvir in patients with psychiatric disorders

P. Belperio, F. Negro, D. Back, 2018 .

Prevalence and type of drug‐drug interactions involving antiretrovirals in patients attending a specialist outpatient clinic in Kampala, Uganda

K. Seden, D. Back, C. Merry, 2012 .

Prevalence and type of drug–drug interactions involving ART in patients attending a specialist HIV outpatient clinic in Kampala, Uganda

K. Seden, S. Khoo, D. Back, 2015, The Journal of antimicrobial chemotherapy.

Clinical pharmacology of oral contraceptive steroids: drug interactions

A. Breckenridge, D. Back, M. Orme, 1980 .

Concentration of ethinyl estradiol in the serum of 31 young women following a treatment period of 3 months with two low-dose oral contraceptives in an intraindividual cross-over design.

D. Back, W. Kuhnz, T. Louton, 1991, Hormone Research.

New drug interactions in HIV and HCV

D. Back, 2012, Retrovirology.

Improved tolerability of ritonavir derived from pharmacokinetic principles.

D. Back, C. Merry, M. Barry, 1996, British Journal of Clinical Pharmacology.

Raltegravir Is a Substrate for the Influx Transporters OAT1 and PEPT1 and the Efflux Transporter Pgp, but Is Not Transported by OATP1A2, OATP1B1, OATP1B3, OCT1, NTCP, or PEPT2

S. Khoo, A. Owen, N. Liptrott, 2010 .

Pharmacokinetics and protein binding of 3-ketodesogestrel and gestodene in the serum of women during 6 cycles of treatment with two low dose oral contraceptives

D. Back, E. Daume, A. Neiss, 1993, Advances in contraception : the official journal of the Society for the Advancement of Contraception.

Plasma concentrations of 3-keto-desogestrel after oral administration of desogestrel and intravenous administration of 3-keto-desogestrel.

D. Back, M. Orme, S. Grimmer, 1987, Contraception.

A non-chromatographic radioimmunoassay for 3-oxo desogestrel.

D. Back, M. Shaw, M. Orme, 1985, Journal of steroid biochemistry.

A randomized trial comparing regimens of four reverse transcriptase inhibitors given together or cyclically in HIV-1 infection - The Quattro Trial

D. Jeffries, A. Breckenridge, C. Loveday, 1999 .

Effects of age on antiretroviral plasma drug concentration in HIV-infected subjects undergoing routine therapeutic drug monitoring.

B. Gazzard, C. Leen, A. Winston, 2013, The Journal of antimicrobial chemotherapy.

How important is the pharmacokinetics issue for the pharmacodynamic diversity of oral contraceptives

D. Back, 1996 .

The influence of secretin on the elimination of14C-Edrophonium in bile

D. Back, T. N. Calvey, 1972, Experientia.

Biliary excretion of [14C]edrophonium and its glucuronide conjugate

D. Back, T. N. Calvey, 1971, The Journal of pharmacy and pharmacology.

Brief Report: Pharmacokinetic/Pharmacodynamic Investigation of Single-Dose Oral Maraviroc in the Context of HIV-1 Pre-exposure Prophylaxis

S. Khoo, C. Herrera, J. Fox, 2016, Journal of acquired immune deficiency syndromes.

Prevalence of drug interactions between antiretroviral and co - administered drugs in Kenya

S. Khoo, S. Kimaiyo, A. Owen, 2008 .

Lopinavir/ritonavir single agent therapy as a universal combination antiretroviral therapy stopping strategy: results from the STOP 1 and STOP 2 studies.

A. Owen, D. Back, Stephen Taylor, 2012, The Journal of antimicrobial chemotherapy.

Re: 'Pharmacokinetic interactions between sildenafil and saquinavir/ritonavir'.

D. Back, 2000, British journal of clinical pharmacology.

The in‐vitro mucosal conjugation of ethinyloestradiol and the bioavailability of oral contraceptive steroids in patients with treated and untreated coeliac disease

D. Back, M. Orme, I. Gilmore, 1992, Alimentary pharmacology & therapeutics.

Alpha 1-acid glycoprotein levels in human immunodeficiency virus-infected subjects on antiretroviral regimens.

G. di Perri, M. Boffito, D. Back, 2002, Drug metabolism and disposition: the biological fate of chemicals.

Drug Interactions in Infectious Diseases, 2nd edn

D. Back, 2006 .

The effect of some benzimidazoles on the disposition of antipyrine and tolbutamide from the rat isolated perfused liver

D. Back, G. Mihaly, S. Ward, 1985, The Journal of pharmacy and pharmacology.

Oral contraceptive steroid plasma concentrations in smokers and non-smokers.

A. Breckenridge, D. Back, F. Crawford, 1981, British medical journal.

Drug interactions in HIV infection

D. Back, M. Barry, S. Gibbons, 1999 .

Reply to "Debilitating fatigue as a treatment indication in chronic hepatitis C".

J. Pawlotsky, X. Forns, C. Sarrazin, 2015, Journal of hepatology.

Rilpivirine Inhibits Drug Transporters ABCB1, SLC22A1, and SLC22A2 In Vitro

A. Owen, N. Liptrott, D. Back, 2013, Antimicrobial Agents and Chemotherapy.

Rilpivirine Inhibits Drug Transporters ABCB 1 , SLC 22 A 1 , and SLC 22 A 2 In Vitro

A. Owen, N. Liptrott, D. Back, 2013 .

A Longitudinal Study of Maternal Dose Response to Low Molecular Weight Heparin in Pregnancy

D. Back, S. Quenby, C. Toh, 2003, Obstetrics and gynecology.

Drug-drug interactions that matter.

D. Back, 2006, Topics in HIV medicine : a publication of the International AIDS Society, USA.

The rabbit study: ritonavir and saquinavir in combination in saquinavir-experienced and previously untreated patients.

B. Larder, S. Bloor, J. Weber, 1999, AIDS research and human retroviruses.

Expression of P-glycoprotein and multidrug resistance-associated protein in healthy volunteers and HIV-infected patients.

S. Khoo, D. Back, P. Hoggard, 2001, AIDS research and human retroviruses.

Metabolism of didanosine (ddI) by erythrocytes: pharmacokinetic implications.

N. Beeching, D. Back, M. Barry, 1993, British Journal of Clinical Pharmacology.

The interaction of antibiotics with synthetic steroids in the rat [proceedings].

A. Breckenridge, D. Back, F. Crawford, 1978, British Journal of Pharmacology.

Different methods to calculate the inhibitory quotient of boosted single protease inhibitors and their association with virological response.

B. Gazzard, A. Winston, S. Khoo, 2006, Journal of acquired immune deficiency syndromes.

Maraviroc: Pharmacokinetics and drug Interactions

D. Back, M. Vourvahis, S. Abel, 2009, Antiviral therapy.

Validation of a rapid and sensitive high-performance liquid chromatography-tandem mass spectrometry (HPLC-MS/MS) assay for the simultaneous determination of existing and new antiretroviral compounds.

S. Khoo, D. Back, M. Siccardi, 2010, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

Pharmacokinetics and pharmacodynamics of the nucleoside sparing dual regimen containing rilpivirine plus darunavir/ritonavir in treatment-naïve HIV-1-infected individuals

S. Khoo, M. Boffito, D. Back, 2018, HIV clinical trials.

Effect of nondisclosure of HIV status in sexual health clinics on unlinked anonymous HIV prevalence estimates in England, 2005–2009

A. Sullivan, D. Back, C. Lowndes, 2015, AIDS.

No pharmacokinetic interaction between raltegravir and amlodipine: importance for co-prescribing in ageing HIV-infected individuals.

S. Khoo, G. di Perri, M. Boffito, 2014, AIDS.

Non-disclosure of HIV status in UK sexual health clinics—a pilot study to identify non-disclosure within a national unlinked anonymous seroprevalence survey

A. Sullivan, D. Back, O. N. Gill, 2013, Sexually Transmitted Infections.

Pharmacokinetics and safety of the co-administration of the antiretroviral raltegravir and the lipid-lowering drug ezetimibe in healthy volunteers.

B. Gazzard, M. Boffito, D. Back, 2011, The Journal of antimicrobial chemotherapy.

Factors influencing lopinavir and atazanavir plasma concentration.

B. Gazzard, C. Leen, D. Pillay, 2010, The Journal of antimicrobial chemotherapy.

Investigation of low-dose ritonavir on human peripheral blood mononuclear cells using gene expression whole genome microarrays.

B. Gazzard, L. Waters, M. Boffito, 2010, Genomics.

Pharmacokinetics of Atazanavir/Ritonavir Once Daily and Lopinavir/Ritonavir Twice and once Daily over 72 h following drug Cessation

B. Gazzard, S. Khoo, M. Boffito, 2008, Antiviral therapy.

CYP3A4*22 (c.522-191 C>T; rs35599367) is associated with lopinavir pharmacokinetics in HIV-positive adults.

S. Khoo, A. Owen, D. Back, 2014, Pharmacogenetics and genomics.

Cobicistat versus ritonavir boosting and differences in the drug-drug interaction profiles with co-medications.

C. Marzolini, S. Khoo, D. Back, 2016, The Journal of antimicrobial chemotherapy.

Prevalence of Potential Drug-Drug Interactions Involving Antiretroviral Drugs in a Large Kenyan Cohort

K. Seden, S. Khoo, S. Kimaiyo, 2011, PloS one.

Safety perspectives on presently considered drugs for the treatment of COVID‐19

M. Pirmohamed, A. Alfirevic, A. Owen, 2020, British journal of pharmacology.

Raltegravir Is a Substrate for SLC22A6: a Putative Mechanism for the Interaction between Raltegravir and Tenofovir

Darren L. Smith, S. Khoo, A. Owen, 2010, Antimicrobial Agents and Chemotherapy.

Drug interactions with oral contraceptive steroids.

A. Breckenridge, D. Back, M. Orme, 1983, IPPF medical bulletin.

The interaction of phenytoin and carbamazepine with oral contraceptive steroids

D. Back, M. Orme, D. Chadwick, 1990 .

A Multiple Dose Phase 1 Assessment of Rilpivirine Long-Acting in a Model of Pre-Exposure Prophylaxis against HIV.

Ross D. Cranston, Kaleab Z. Abebe, S. Khoo, 2019, AIDS research and human retroviruses.

Long-acting rilpivirine as potential pre-exposure prophylaxis for HIV-1 prevention (the MWRI-01 study): an open-label, phase 1, compartmental, pharmacokinetic and pharmacodynamic assessment.

Ross D. Cranston, Kaleab Z. Abebe, S. Khoo, 2016, The lancet. HIV.